James Gallo
Psychiatry · Warwick, RINPI 1801978622
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 167 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 31.2% of the total. Reporting peaked in 2019 at $1,690 and has fallen 58.9% since, to $694 in 2025. Among psychiatry clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 167 payments — averaging $23.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Ironshore Pharmaceuticals Inc.$509
- Johnson & Johnson$322
- Indivior Inc.$319
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$240
- Vanda Pharmaceuticals Inc.$171
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,892100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 67 | $1,216 |
| Ironshore Pharmaceuticals Inc. | 13 | $509 |
| Johnson & Johnson | 15 | $322 |
| Indivior Inc. | 11 | $319 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $240 |
| Vanda Pharmaceuticals Inc. | 4 | $171 |
| Neurocrine Biosciences, Inc. | 4 | $170 |
| Otsuka America Pharmaceutical, Inc. | 4 | $165 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $120 |
| Shire North American Group Inc | 5 | $75 |
| Axsome Therapeutics, Inc. | 4 | $72 |
| Avanir Pharmaceuticals, Inc. | 4 | $72 |
| Merz North America, Inc. | 5 | $65 |
| Kaleo, Inc. | 3 | $51 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Braeburn Inc. | 2 | $50 |
| MDD US Operations, LLC | 3 | $45 |
| Corium, LLC | 2 | $40 |
| Supernus Pharmaceuticals, Inc. | 2 | $35 |
| Orexo US, Inc. | 3 | $33 |
| Neos Therapeutics, LP | 2 | $31 |
| Bausch Health US, LLC | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Lundbeck LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,892 in reported general payments places this provider in the 90th percentile of 209 psychiatry providers in Rhode Island.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 77 | $12,309 |
| Aripiprazole | 90 | $9,637 |
| VyvanseLisdexamfetamine Dimesylate | 21 | $7,667 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 41 | $3,796 |
| Dextroamphetamine Sulfate ErDextroamphetamine Sulfate | 11 | $3,291 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 102 | $2,910 |
| Lisdexamfetamine Dimesylate | 12 | $2,817 |
| Bupropion XlBupropion Hcl | 93 | $2,227 |
| Lamotrigine | 65 | $2,094 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 69 | $2,033 |
| Alprazolam | 274 | $1,921 |
| Buprenorphine Hcl | 51 | $1,769 |
| Quetiapine Fumarate | 48 | $1,526 |
| Gabapentin | 96 | $1,438 |
| Duloxetine Hcl | 54 | $1,424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $120 | $7,66721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 209 psychiatry providers in Rhode Island.
Other psychiatry in Warwick
- Warren OngWarwick$807K
- Liliya KoyfmanWarwick$110K
- Terrie MailhotWarwick$26K
- Ethan KischWarwick$24K
- David KroesslerWarwick$3K
- Charles DenbyWarwick$2K
- Sandhya PatelWarwick$2K
- Alexander ScagnelliWarwick$983
- Richard WhalenWarwick$661
- Rafael TorresWarwick$476
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.